1. Home
  2. Live Updates
  3. Respiratory tract diseases

Live Breaking News & Updates on Respiratory tract diseases

Stay informed with the latest breaking news from Respiratory tract diseases on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Respiratory tract diseases and stay connected to the pulse of your community

CDC Meeting on RSV Vaccines Could Be Pivotal for GSK, Moderna

The agency’s vaccine advisory committee could offer clues about an eventual call on how often the vaccines are needed.

Michael-yee , Josh-nathan-kazis , Advisory-committee-on-immunization-practices , Drug-administration , Centers-for-disease , Pfizer , Getty-images , Disease-control , Advisory-committee , Immunization-practices , Article-normal , Biotechnology-services

Pfizer Stock Has 29% Upside, Says a New Bull

Guggenheim analysts initiated coverage of drug firm Pfizer at Buy with a $36 price target. Shares have lagged behind the market in recent years.

Emily-dattilo , Pfizer , Courtesy-pfizer , Vamil-divan , Dow-jones-market , Wall-street , Article-normal , Pharmaceuticals , Vaccines , Textiles , Wholesalers

Moderna posts surprise quarterly profit even as COVID sales continue to slide

Moderna on Thursday reported a surprise fourth-quarter profit even as its COVID product sales continue to plunge.

Moderna-spikevax , Stephane-bancel , Centers-for-disease , Drug-administration , Merck-co , Vaccine-alliance , Moderna-inc , Chief-financial-officer-jamey-mock , Executive-stephane-bancel , Disease-control , Article-normal , Biotechnology

Moderna Stock Jumps on Surprise Profit, Sales Ahead of Expectations

Vaccine maker Moderna reported a profit of 55 cents a share on revenue of $2.8 billion in the December quarter, beating analysts’ expectations.

Jack-denton , Getty-images , Wall-street , Article-normal , Biotechnology-services , Pharmaceuticals , Vaccines , Healthcare-life-sciences , Specialized-drugs-medications , Financial-performance , Earnings

Novavax Stock Soars 26%. A Vaccine Purchase Settlement Is One Reason Why.

Novavax reaches a settlement related to an advance purchase agreement with Gavi.

John-jacobs , Angela-palumbo , Drug-administration , Getty-images , Novavax-chief-executive , Dow-jones-market , Wall-street , Article-normal , Pharmaceuticals , Vaccines , Textiles , Healthcare-life-sciences

Sonic Healthcare 1H Net Profit A$202.3 Million, Down 47% on Year

By David Winning SYDNEY--Sonic Healthcare said its net profit fell by 47% on a steep drop in Covid-19 testing volumes, but it has benefited from recent...

Australia , Sydney , New-south-wales , Australian , Colin-goldschmidt , Sonic-healthcare , Utah-based-pathology-watch , Executive-colin-goldschmidt , David-winning , Article-normal , Healthcare-life-sciences

RAPT Therapeutics stock plunges as FDA halts two clinical trials

RAPT Therapeutics shares dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its...

Brian-wong , Rapt-therapeutics-inc , Drug-administration , Goldman-sachs , Article-normal , Biotechnology-services , Pharmaceuticals , Computers-consumer-electronics , Software , Applications-software , Healthcare-life-sciences , Biopharmaceuticals

DaVita Stock Gains. Volumes Are Improving After Covid-19.

DaVita expects to earnings to be between $8.70 a share and $9.80 a share for the full year.

David-macdonald , Javier-rodriguez , Kevin-fischbeck , Angela-palumbo , Wall-street , Truist-securities , Article-normal , Printing-publishing , Media-entertainment , Financial-performance , Share-price-movement-disruptions

Expanding the child tax credit could come from axing this fraud 'magnet'

Congress is considering a new bipartisan tax package that would expand the child tax credit and restore several business tax breaks, and the plan is to end a...

United-states , Ukraine , Washington , American , Henrietta-treyz , Maya-macguineas , John-buhl , Steve-pavlick , Danny-werfel , Committee-on-taxation , Tax-foundation , Renaissance-macro-research

Kenvue 4Q Net Down on Later Start to Flu Season

By Rob Curran Kenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, said fourth-quarter net income fell slightly as a later start to flu...

Japan , China , Japanese , Rob-curran , Johnson , Wall-street , Article-normal , Cosmetics-toiletries , Consumer-goods , Personal-care-products-appliances , Political-general-news , Respiratory-tract-diseases